US earmarks flu cash

O'Driscoll, Cath
May 2006
ICIS Chemical Business;5/15/2006, Vol. 1 Issue 19, p33
Trade Publication
The article reports that the U.S. government is stepping up efforts against a threatened flu pandemic by handing out contracts to speed the development and production of vaccines. The five firms awarded contracts, including GlaxoSmithKline, MedImmune, Novartis, DynPort Vaccine and Solvay have each received funding to support newer cell-based technologies for producing the vaccines. Compared with traditional methods of making flu vaccines in eggs, cell-based culture should allow the vaccines to be made in weeks rather than months. Flu cell culture could represent the next generation of flu vaccines.


Related Articles

  • Contract signing.  // Pharmaceutical Technology;Jun2005, Vol. 29 Issue 6, p72 

    This article reports that DVC LLC, a subsidiary of Computer Sciences Corp., has been awarded a two-year, $19.6-million contract from the Department of Defense Medical Identification and Treatment Systems Joint Product Management Office to develop plasma-derived human butyrylcholinesterase. Under...

  • FDA to review DynPort's smallpox drug.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p12 

    Reports on the application to be reviewed by the U.S. Food and Drug Administration for Vaccinia Immune Globulin, an intravenous immune globulin under evaluation for the treatment of adverse reactions to smallpox vaccination, from DynPort Vaccine Co. Manufacture of drug from plasma donations of...

  • DynPort completes preclinical testing of plague vaccine candidate.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p7 

    Reports on the effort of DynPort Vaccine Co. LLC, a joint venture between Computer Sciences Corp. and Porton International, to demonstrate the efficacy of its recombinant plague vaccine in the U.S. Critical step in the development of a plague vaccine for human use; Correlation between the...

  • Vaccine Production Using Single Use Disposable Technology. Smart, Nigel J. // Pharmaceutical Processing;Jan/Feb2013, Vol. 28 Issue 1, p26 

    The article discusses the status and future prospects of single use disposable vaccine production. It explores the advantages of producing single use disposable systems and the reasons for increasing use of disposable system components for both biotherapeutic developers and vaccine producers...

  • "Stable Liquid" Technology Permits Heptavalent Botulism Vaccine. Bush, Laura // Pharmaceutical Technology;Apr2005, Vol. 29 Issue 4, p28 

    The article informs that the U.S. National Institute of Allergy and Infectious Diseases has awarded a $5.4-million grant to the DynPort Vaccine Company LLC to develop a new heptavalent vaccine against botulism. The vaccine will be stabihzed using stable liquid technology owned by Cambridge...

  • Solvay Vaccine Facility To Use Mammalian Cell Culture.  // Chemical Market Reporter;2/3/2003, Vol. 263 Issue 5, p4 

    Reports on the plans of Solvay to move into mammalian cell culture and build an integrated facility for the production of influenza vaccines in Netherlands. Usability of the mammalian cell lines; Commercial production of the vaccines; Efforts of the World Health Organization to encourage...

  • CLINIC ROUNDUP.  // BioWorld Today;3/15/2010, Vol. 21 Issue 49, p8 

    This section offers clinical trial news briefs in the biotechnology industry as of March 15, 2010, including the positive Phase III study data for Preflucel, a trivalent seasonal influenza candidate vaccine, jointly presented by Baxter International Inc. and DynPort Vaccine Co. LLC, Phase II...

  • Government Work 'Easy Money'? Don't Bet Your R&D Budget on it. Young, Donna // BioWorld Today;1/28/2010, Vol. 21 Issue 18, p1 

    The article presents the views of DynPort Vaccine Co. president Robert House on the challenges and risks faced by the biotechnology industry when dealing with the U.S. government. House told an audience at the 2010 Phacilitate Vaccine Forum not to assume that their firms know the needs of the...

  • Clinic Roundup.  // BioWorld Today;10/7/2010, Vol. 21 Issue 194, p8 

    This section offers news briefs concerning clinical trials. Adeona Pharmaceuticals Inc. has finished enrollment in the second portion of its clinical trial on an oral zinc cysteine for Alzheimer's disease treatment. Caris Life Sciences Inc.'s pilot study revealed that personalized cancer therapy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics